Biodegradable drug delivery compositions

Abstract

A biodegradable drug delivery compositions comprising a triblock copolymer containing a polyester and a polyethylene glycol and a diblock copolymer containing a polyester and an end-capped polyethylene glycol, as well as a pharmaceutically active principle is disclosed.

1 - 43 . (canceled) 
     
     
         44 . A syringe comprising a biodegradable drug delivery composition comprising
 (a) a biodegradable triblock copolymer having the formula: poly(lactic acid)v-poly(ethylene glycol), w, -poly(lactic acid)x. wherein v and x are the number of repeat units ranging from 24 to 682 and w is the number of repeat units ranging from 4 to 273 and v=x or v≠x;   (b) a biodegradable diblock copolymer having the formula: methoxy poly(ethylene glycol)y-poly(lactic acid)z, wherein y and z are the number of repeat units, with y ranging from 3 to 45 and z ranging from 7 to 327, wherein the ratio of the biodegradable triblock copolymer of (a) and the biodegradable diblock copolymer of (b) is 1:3 to 1:8 or 1:1 to 1:19 or 3:2 to 1:19 in said biodegradable drug composition, which is insoluble in an aqueous environment; and   (c) risperidone (Example 6)   
     
     
         45 . The syringe according to  claim 44  wherein the risperidone is present at 10 to 200 mg/ml. (page 24, lines 14-15) 
     
     
         46 . The syringe according to  claim 44  wherein the biodegradable drug delivery composition delivers the risperidone for at least 7 days when administered to a patient. (page 25, lines 7-8) 
     
     
         47 . The syringe according to  claim 44  wherein the biodegradable drug delivery composition delivers the risperidone for at least 30 days when administered to a patient. ( FIGS. 32 and 33 ) 
     
     
         48 . A method of administering risperidone to a patient in need thereof which comprises injecting said patient using the syringe according to  claim 44  to the biodegradable drug delivery composition containing risperidone. 
     
     
         49 . A method of treating a condition which is responsive to risperidone which comprises administering to a patient in need thereof a biodegradable drug delivery composition comprising (a) a biodegradable triblock copolymer having the formula: poly(lactic acid)v-poly(ethylene glycol), w, -poly(lactic acid)x. wherein v and x are the number of repeat units ranging from 24 to 682 and w is the number of repeat units ranging from 4 to 273 and v=x or v≠x; (b) a biodegradable diblock copolymer having the formula: methoxy poly(ethylene glycol)y-poly(lactic acid)z, wherein y and z are the number of repeat units, with y ranging from 3 to 45 and z ranging from 7 to 327, wherein the ratio of the biodegradable triblock copolymer of (a) and the biodegradable diblock copolymer of (b) is 1:3 to 1:8 or 1:1 to 1:19 or 3:2 to 1:19 in said biodegradable drug composition, which is insoluble in an aqueous environment; and (c) risperidone. 
     
     
         50 . The method according to  claim 49 , wherein said biodegradable drug delivery composition is administered using a syringe. 
     
     
         51 . A drug implant comprising
 (a) a biodegradable triblock copolymer having the formula: poly(lactic acid)v-poly(ethylene glycol), w, -poly(lactic acid)x. wherein v and x are the number of repeat units ranging from 24 to 682 and w is the number of repeat units ranging from 4 to 273 and v=x or v≠x;   (b) a biodegradable diblock copolymer having the formula: methoxy poly(ethylene glycol)y-poly(lactic acid)z, wherein y and z are the number of repeat units, with y ranging from 3 to 45 and z ranging from 7 to 327, wherein the ratio of the biodegradable triblock copolymer of (a) and the biodegradable diblock copolymer of (b) is 1:3 to 1:8 or 1:1 to 1:19 or 3:2 to 1:19; and   (c) risperidone.   
     
     
         52 . The drug implant according to  claim 51  wherein the risperidone is present at 10 to 200 mg/ml.